A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY OF INEBILIZUMAB EFFICACY AND SAFETY IN IGG4 RELATED DISEASE

Registry ID

VIB0551.P3.S2

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

HORIZON THERAPEUTICS IRELAND DAC

Start date

2023-03-13

Last update

2020-07-20

Conditions

• IGG4 RELATED DISEASE

Related clinical trials

• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH IGG4-RELATED DISEASE (INDIGO)

View on source registry